<p><strong>CASI Pharmaceuticals, Inc.</strong>（纳斯达克代码：CASI）的股东们看到股价在过去一个月内大幅下跌 43%，并且抹去了之前的正面表现，肯定不会感到高兴。这一近期的下跌使得股东们在过去一年中面临了灾难性的 79% 的损失。</p>
<p>由于股价大幅下跌，CASI Pharmaceuticals 目前可能发出非常看涨的信号，其市销率（&#34;P/S&#34;）为 0.6 倍，因为在美国生物技术行业中，几乎一半的公司市销率超过 10 倍，甚至市销率高达 86 倍的情况也并不少见。然而，市销率可能较低是有原因的，需要进一步调查以确定其合理性。</p>
<p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>查看我们对 CASI Pharmaceuticals 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/354853-ps-multiple-vs-industry-1-dark-2/1759236687145?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/354853-ps-multiple-vs-industry-1-dark-2/1759236687145"/></p>
<p>纳斯达克 CM:CASI 市销率与行业比较 2025 年 9 月 30 日</p>
<h3>CASI Pharmaceuticals 的表现如何</h3>
<p>CASI Pharmaceuticals 的表现可以更好，因为其收入增长低于最近大多数其他公司。似乎许多人预计这种乏善可陈的收入表现将持续下去，这抑制了市销率的增长。如果你仍然喜欢这家公司，你会希望收入不会变得更糟，并且能够在公司不受欢迎时买入一些股票。</p>
<p>想要了解分析师对公司的完整预测吗？那么我们 <strong>免费的</strong>CASI Pharmaceuticals 报告将帮助你揭示未来的趋势。</p>
<h2>CASI Pharmaceuticals 的收入增长趋势如何？</h2>
<p>为了证明其市销率的合理性，CASI Pharmaceuticals 需要实现远低于行业水平的微弱增长。</p>
<p>回顾过去一年，公司收入实现了 37% 的显著增长。然而，与三年前相比，收入总共下降了 9.6%，这相当令人失望。因此，不幸的是，我们必须承认公司在这段时间内未能有效地增长收入。</p>
<p>展望未来，唯一覆盖该公司的分析师的预测显示，收入增长将进入负增长领域，未来三年每年下降 100%。在行业其他公司预计每年增长 128% 的情况下，这并不好。</p>
<p>考虑到这一点，我们发现 CASI Pharmaceuticals 的市销率与其行业同行密切匹配，这一点颇具吸引力。然而，考虑到收入在下滑，市销率是否已经触底并没有保证。如果公司未能改善其收入增长，市销率可能会进一步下降。</p>
<h2>CASI Pharmaceuticals 的市销率对投资者意味着什么？</h2>
<p>CASI Pharmaceuticals 的股票大幅下跌，其市销率也随之下降。虽然市销率不应成为你是否购买股票的决定性因素，但它是收入预期的一个相当有效的晴雨表。</p>
<p>显然，CASI Pharmaceuticals 因其收入下滑的预期而维持低市销率。由于行业内其他公司预测收入增长，CASI Pharmaceuticals 的糟糕前景使其低市销率得到了合理解释。在这种情况下，很难看到股价在短期内强劲上涨。</p>
<p>还有其他重要的风险因素需要考虑，我们发现了 <strong>CASI Pharmaceuticals 的 5 个警告信号</strong>（其中 3 个不可忽视！），在投资之前你应该了解这些。</p>
<p>如果你对 CASI Pharmaceuticals 的业务实力 <strong>不确定</strong>，为什么不探索我们互动式的股票列表，寻找一些你可能错过的基本面稳健的其他公司呢？</p>

CASI制药

<p>CASI 制药（NASDAQ:CASI）在过去一个月的股价下跌了 43%，导致股东在过去一年中损失了 79%。该公司的市销率（P/S）为 0.6 倍，显著低于行业同行，这表明对收入增长的潜在担忧。尽管去年收入增长了 37%，但总收入在三年内下降了 9.6%，预测显示未来三年收入增长将下降 100%。这一疲弱的前景使得低市销率得以合理化，短期内股价难以恢复</p>

<p><strong>CASI Pharmaceuticals, Inc.</strong> (NASDAQ:CASI) shareholders won't be pleased to see that the share price has had a very rough month, dropping 43% and undoing the prior period's positive performance. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 79% loss during that time.</p>
<div class="lb-trans"><p><strong>CASI Pharmaceuticals, Inc.</strong>（纳斯达克代码：CASI）的股东们看到股价在过去一个月内大幅下跌 43%，并且抹去了之前的正面表现，肯定不会感到高兴。这一近期的下跌使得股东们在过去一年中面临了灾难性的 79% 的损失。</p>
</div><p>Since its price has dipped substantially, CASI Pharmaceuticals may be sending very bullish signals at the moment with its price-to-sales (or &#34;P/S&#34;) ratio of 0.6x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 10x and even P/S higher than 86x are not unusual. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>由于股价大幅下跌，CASI Pharmaceuticals 目前可能发出非常看涨的信号，其市销率（&#34;P/S&#34;）为 0.6 倍，因为在美国生物技术行业中，几乎一半的公司市销率超过 10 倍，甚至市销率高达 86 倍的情况也并不少见。然而，市销率可能较低是有原因的，需要进一步调查以确定其合理性。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>Check out our latest analysis for CASI Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对 CASI Pharmaceuticals 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/354853-ps-multiple-vs-industry-1-dark-2/1759236687145" alt="" original-src="https://images.simplywall.st/asset/chart/354853-ps-multiple-vs-industry-1-dark-2/1759236687145"/></p>
<p>NasdaqCM:CASI Price to Sales Ratio vs Industry September 30th 2025</p>
<div class="lb-trans"><p>纳斯达克 CM:CASI 市销率与行业比较 2025 年 9 月 30 日</p>
</div><h3>How CASI Pharmaceuticals Has Been Performing</h3>
<div class="lb-trans"><h3>CASI Pharmaceuticals 的表现如何</h3>
</div><p>CASI Pharmaceuticals could be doing better as it's been growing revenue less than most other companies lately. It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>CASI Pharmaceuticals 的表现可以更好，因为其收入增长低于最近大多数其他公司。似乎许多人预计这种乏善可陈的收入表现将持续下去，这抑制了市销率的增长。如果你仍然喜欢这家公司，你会希望收入不会变得更糟，并且能够在公司不受欢迎时买入一些股票。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on CASI Pharmaceuticals will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析师对公司的完整预测吗？那么我们 <strong>免费的</strong>CASI Pharmaceuticals 报告将帮助你揭示未来的趋势。</p>
</div><h2>How Is CASI Pharmaceuticals' Revenue Growth Trending?</h2>
<div class="lb-trans"><h2>CASI Pharmaceuticals 的收入增长趋势如何？</h2>
</div><p>In order to justify its P/S ratio, CASI Pharmaceuticals would need to produce anemic growth that's substantially trailing the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，CASI Pharmaceuticals 需要实现远低于行业水平的微弱增长。</p>
</div><p>Retrospectively, the last year delivered an exceptional 37% gain to the company's top line. Still, revenue has fallen 9.6% in total from three years ago, which is quite disappointing. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenues over that time.</p>
<div class="lb-trans"><p>回顾过去一年，公司收入实现了 37% 的显著增长。然而，与三年前相比，收入总共下降了 9.6%，这相当令人失望。因此，不幸的是，我们必须承认公司在这段时间内未能有效地增长收入。</p>
</div><p>Shifting to the future, estimates from the only analyst covering the company suggest revenue growth is heading into negative territory, declining 100% each year over the next three years. That's not great when the rest of the industry is expected to grow by 128% each year.</p>
<div class="lb-trans"><p>展望未来，唯一覆盖该公司的分析师的预测显示，收入增长将进入负增长领域，未来三年每年下降 100%。在行业其他公司预计每年增长 128% 的情况下，这并不好。</p>
</div><p>With this in consideration, we find it intriguing that CASI Pharmaceuticals' P/S is closely matching its industry peers. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>考虑到这一点，我们发现 CASI Pharmaceuticals 的市销率与其行业同行密切匹配，这一点颇具吸引力。然而，考虑到收入在下滑，市销率是否已经触底并没有保证。如果公司未能改善其收入增长，市销率可能会进一步下降。</p>
</div><h2>What Does CASI Pharmaceuticals' P/S Mean For Investors?</h2>
<div class="lb-trans"><h2>CASI Pharmaceuticals 的市销率对投资者意味着什么？</h2>
</div><p>Shares in CASI Pharmaceuticals have plummeted and its P/S has followed suit. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.</p>
<div class="lb-trans"><p>CASI Pharmaceuticals 的股票大幅下跌，其市销率也随之下降。虽然市销率不应成为你是否购买股票的决定性因素，但它是收入预期的一个相当有效的晴雨表。</p>
</div><p>It's clear to see that CASI Pharmaceuticals maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. As other companies in the industry are forecasting revenue growth, CASI Pharmaceuticals' poor outlook justifies its low P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>显然，CASI Pharmaceuticals 因其收入下滑的预期而维持低市销率。由于行业内其他公司预测收入增长，CASI Pharmaceuticals 的糟糕前景使其低市销率得到了合理解释。在这种情况下，很难看到股价在短期内强劲上涨。</p>
</div><p>There are also other vital risk factors to consider and we've discovered <strong>5 warning signs for CASI Pharmaceuticals</strong> (3 can't be ignored!) that you should be aware of before investing here.</p>
<div class="lb-trans"><p>还有其他重要的风险因素需要考虑，我们发现了 <strong>CASI Pharmaceuticals 的 5 个警告信号</strong>（其中 3 个不可忽视！），在投资之前你应该了解这些。</p>
</div><p>If you're <strong>unsure about the strength of CASI Pharmaceuticals' business</strong>, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.</p>
<div class="lb-trans"><p>如果你对 CASI Pharmaceuticals 的业务实力 <strong>不确定</strong>，为什么不探索我们互动式的股票列表，寻找一些你可能错过的基本面稳健的其他公司呢？</p>
</div>

由于 CASI 制药公司（NASDAQ:CASI）的股价暴跌 43%，其收入几乎没有引起市场的兴奋